Item 8.01 Other Events.

As previously reported, on November 22, 2022, BioSig Technologies, Inc. (the "Company") received a letter (the "Letter") from The Nasdaq Stock Market ("Nasdaq") informing the Company that the Company failed to maintain a minimum of $2,500,000 in stockholders' equity, as is required for continued listing (the "Stockholders' Equity Requirement") on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(b)(1) and that as of November 22, 2022, the Company did not meet the alternative compliance standards relating to the market value of listed securities or net income from continuing operations (the "Alternative Compliance Standards"). The letter also indicated that the Company had a period of 45 calendar days from the date of the Letter, or until January 6, 2023 (the "Compliance Period"), to submit a plan to regain compliance with the Stockholders' Equity Requirement or the Alternative Compliance Standards (the "Plan"). If the Plan was accepted, Nasdaq could grant an extension of up to 180 calendar days from the date of the Letter for the Company to regain compliance.

On January 17, 2023, the Company received a letter from Nasdaq notifying the Company that the Company has been granted an additional 180-day period, or until May 22, 2023, to regain compliance with the Stockholders' Equity Requirement.

If compliance with the Stockholders' Equity Requirement cannot be demonstrated upon the Company filing its periodic report for the period ending June 30, 2023 with the U.S. Securities and Exchange Commission, the Company may be subject to delisting. Accordingly, there can be no assurance that the Company will be able to regain compliance with the Nasdaq listing rules or maintain its listing on the Nasdaq Stock Market.

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses